Risk Factors for Immune Checkpoint Inhibitor-Induced Liver Injury and the Significance of Liver Biopsy

Immune checkpoint inhibitor (ICI)-induced liver injury (LI) is a common adverse event, but the clinical characteristics based on the classification of hepatocellular injury and cholestatic types are not fully evaluated. This study aims to analyze risk factors and histological findings in relation to...

Full description

Bibliographic Details
Published in:Diagnostics
Main Authors: Miki Kawano, Yoshihiko Yano, Atsushi Yamamoto, Eiichiro Yasutomi, Yuta Inoue, Jun Kitadai, Ryutaro Yoshida, Takanori Matsuura, Yuuki Shiomi, Yoshihide Ueda, Yuzo Kodama
Format: Article
Language:English
Published: MDPI AG 2024-04-01
Subjects:
Online Access:https://www.mdpi.com/2075-4418/14/8/815
_version_ 1850059868337078272
author Miki Kawano
Yoshihiko Yano
Atsushi Yamamoto
Eiichiro Yasutomi
Yuta Inoue
Jun Kitadai
Ryutaro Yoshida
Takanori Matsuura
Yuuki Shiomi
Yoshihide Ueda
Yuzo Kodama
author_facet Miki Kawano
Yoshihiko Yano
Atsushi Yamamoto
Eiichiro Yasutomi
Yuta Inoue
Jun Kitadai
Ryutaro Yoshida
Takanori Matsuura
Yuuki Shiomi
Yoshihide Ueda
Yuzo Kodama
author_sort Miki Kawano
collection DOAJ
container_title Diagnostics
description Immune checkpoint inhibitor (ICI)-induced liver injury (LI) is a common adverse event, but the clinical characteristics based on the classification of hepatocellular injury and cholestatic types are not fully evaluated. This study aims to analyze risk factors and histological findings in relation to the classification of ICI-induced LI. In total, 254 ICI-induced LI patients among 1086 treated with ICIs between September 2014 and March 2022 were classified according to the diagnostic criteria for drug-induced LI (DILI), and their risk factors and outcomes were evaluated. Kaplan–Meier analyses showed that overall survival in patients with hepatocellular-injury-type LI was significantly longer than others (<i>p</i> < 0.05). Regarding pre-treatment factors, the lymphocyte count was significantly higher in patients with ICI-induced LI, especially in hepatocellular-injury-type LI. Gamma glutamyl transferase (γGTP) and alkaline phosphatase (ALP) were also significantly lower in patients with ICI-induced LI (<i>p</i> < 0.05). Multivariate analyses revealed that malignant melanoma, high lymphocyte count, and low ALP levels were extracted as factors contributing to hepatocellular-injury-type LI. The histological findings among 37 patients diagnosed as ICI-induced LI via liver biopsy also revealed that the spotty/focal necrosis was significantly frequent in hepatocellular-injury-type LI, whereas ductular reactions were frequently observed in cholestatic-type LI. It is suggested that the histological inflammation pattern in patients with LI is closely correlated with the type of DILI.
format Article
id doaj-art-e9709c65e4fb4d12ae4cd493d1f2cfae
institution Directory of Open Access Journals
issn 2075-4418
language English
publishDate 2024-04-01
publisher MDPI AG
record_format Article
spelling doaj-art-e9709c65e4fb4d12ae4cd493d1f2cfae2025-08-20T00:22:36ZengMDPI AGDiagnostics2075-44182024-04-0114881510.3390/diagnostics14080815Risk Factors for Immune Checkpoint Inhibitor-Induced Liver Injury and the Significance of Liver BiopsyMiki Kawano0Yoshihiko Yano1Atsushi Yamamoto2Eiichiro Yasutomi3Yuta Inoue4Jun Kitadai5Ryutaro Yoshida6Takanori Matsuura7Yuuki Shiomi8Yoshihide Ueda9Yuzo Kodama10Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe 650-0017, JapanDivision of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe 650-0017, JapanDivision of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe 650-0017, JapanDepartment of Gastroenterology, Hyogo Prefectural Kakogawa Medical Center, Kakogawa 675-8555, JapanDivision of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe 650-0017, JapanDivision of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe 650-0017, JapanDivision of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe 650-0017, JapanDivision of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe 650-0017, JapanDivision of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe 650-0017, JapanDivision of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe 650-0017, JapanDivision of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe 650-0017, JapanImmune checkpoint inhibitor (ICI)-induced liver injury (LI) is a common adverse event, but the clinical characteristics based on the classification of hepatocellular injury and cholestatic types are not fully evaluated. This study aims to analyze risk factors and histological findings in relation to the classification of ICI-induced LI. In total, 254 ICI-induced LI patients among 1086 treated with ICIs between September 2014 and March 2022 were classified according to the diagnostic criteria for drug-induced LI (DILI), and their risk factors and outcomes were evaluated. Kaplan–Meier analyses showed that overall survival in patients with hepatocellular-injury-type LI was significantly longer than others (<i>p</i> < 0.05). Regarding pre-treatment factors, the lymphocyte count was significantly higher in patients with ICI-induced LI, especially in hepatocellular-injury-type LI. Gamma glutamyl transferase (γGTP) and alkaline phosphatase (ALP) were also significantly lower in patients with ICI-induced LI (<i>p</i> < 0.05). Multivariate analyses revealed that malignant melanoma, high lymphocyte count, and low ALP levels were extracted as factors contributing to hepatocellular-injury-type LI. The histological findings among 37 patients diagnosed as ICI-induced LI via liver biopsy also revealed that the spotty/focal necrosis was significantly frequent in hepatocellular-injury-type LI, whereas ductular reactions were frequently observed in cholestatic-type LI. It is suggested that the histological inflammation pattern in patients with LI is closely correlated with the type of DILI.https://www.mdpi.com/2075-4418/14/8/815immune checkpoint inhibitorliver injuryDILIhistology
spellingShingle Miki Kawano
Yoshihiko Yano
Atsushi Yamamoto
Eiichiro Yasutomi
Yuta Inoue
Jun Kitadai
Ryutaro Yoshida
Takanori Matsuura
Yuuki Shiomi
Yoshihide Ueda
Yuzo Kodama
Risk Factors for Immune Checkpoint Inhibitor-Induced Liver Injury and the Significance of Liver Biopsy
immune checkpoint inhibitor
liver injury
DILI
histology
title Risk Factors for Immune Checkpoint Inhibitor-Induced Liver Injury and the Significance of Liver Biopsy
title_full Risk Factors for Immune Checkpoint Inhibitor-Induced Liver Injury and the Significance of Liver Biopsy
title_fullStr Risk Factors for Immune Checkpoint Inhibitor-Induced Liver Injury and the Significance of Liver Biopsy
title_full_unstemmed Risk Factors for Immune Checkpoint Inhibitor-Induced Liver Injury and the Significance of Liver Biopsy
title_short Risk Factors for Immune Checkpoint Inhibitor-Induced Liver Injury and the Significance of Liver Biopsy
title_sort risk factors for immune checkpoint inhibitor induced liver injury and the significance of liver biopsy
topic immune checkpoint inhibitor
liver injury
DILI
histology
url https://www.mdpi.com/2075-4418/14/8/815
work_keys_str_mv AT mikikawano riskfactorsforimmunecheckpointinhibitorinducedliverinjuryandthesignificanceofliverbiopsy
AT yoshihikoyano riskfactorsforimmunecheckpointinhibitorinducedliverinjuryandthesignificanceofliverbiopsy
AT atsushiyamamoto riskfactorsforimmunecheckpointinhibitorinducedliverinjuryandthesignificanceofliverbiopsy
AT eiichiroyasutomi riskfactorsforimmunecheckpointinhibitorinducedliverinjuryandthesignificanceofliverbiopsy
AT yutainoue riskfactorsforimmunecheckpointinhibitorinducedliverinjuryandthesignificanceofliverbiopsy
AT junkitadai riskfactorsforimmunecheckpointinhibitorinducedliverinjuryandthesignificanceofliverbiopsy
AT ryutaroyoshida riskfactorsforimmunecheckpointinhibitorinducedliverinjuryandthesignificanceofliverbiopsy
AT takanorimatsuura riskfactorsforimmunecheckpointinhibitorinducedliverinjuryandthesignificanceofliverbiopsy
AT yuukishiomi riskfactorsforimmunecheckpointinhibitorinducedliverinjuryandthesignificanceofliverbiopsy
AT yoshihideueda riskfactorsforimmunecheckpointinhibitorinducedliverinjuryandthesignificanceofliverbiopsy
AT yuzokodama riskfactorsforimmunecheckpointinhibitorinducedliverinjuryandthesignificanceofliverbiopsy